Defence Therapeutics (DTC) Financial Statements
Defence Therapeutics Financial Overview
Defence Therapeutics's market cap is currently $16.94M. The company's EPS TTM is $-0.11; its P/E ratio is -3.17; Defence Therapeutics has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 26 | Sep 25 | Jun 24 | Sep 23 | Sep 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -72.11K | $ -72.34K | $ -90.92K | $ -13.82K | $ 0.00 |
| Operating Income | $ -4.99M | $ -3.27M | $ -12.66M | $ -6.55M | $ -3.56M |
| EBITDA | $ -4.92M | $ -3.13M | $ -12.66M | $ -6.48M | $ 0.00 |
| Net Income | $ -6.70M | $ -3.52M | $ -13.19M | $ -6.76M | $ -7.34M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.88M | $ 1.23M | $ 56.55K | $ 2.79M | $ 506.70K |
| Total Assets | $ 6.51M | $ 1.65M | $ 477.75K | $ 3.53M | $ 719.67K |
| Total Debt | $ 1.72M | $ 1.50M | $ 1.75M | $ 1.75M | $ 0.00 |
| Net Debt | $ -161.32K | $ 271.84K | $ 1.69M | $ -1.05M | $ -506.70K |
| Total Liabilities | $ 3.00M | $ 2.91M | $ 4.06M | $ 1.97M | $ 1.11M |
| Stockholders' Equity | $ 3.51M | $ -1.26M | $ -3.58M | $ 1.57M | $ -387.56K |
| Cash Flow | |||||
| Free Cash Flow | $ -4.76M | $ -3.40M | $ -4.49M | $ -7.72M | $ -6.04M |
| Operating Cash Flow | $ -4.34M | $ -3.40M | $ -4.29M | $ -7.66M | $ -6.04M |
| Investing Cash Flow | $ -419.63K | $ 3.60K | $ -203.24K | $ -65.80K | $ 0.00 |
| Financing Cash Flow | $ 5.42M | $ 4.57M | $ 1.76M | $ 10.01M | $ 1.10M |
Currency in CAD